Corner Therapeutics is the immunotherapy company unlocking lifelong protection from cancer and infectious diseases. Using its novel dendritic cell stimuli platforms, Corner teaches the immune system to engineer its own long-lived, disease-fighting T cells. Corner's technology solves the 'last mile' problem that has kept researchers from achieving the holy grails of medicine: therapeutic cancer and infectious disease vaccines that provide life-long immunity. With its antigen-agnostic platform, Corner is revolutionizing care for an exceptionally wide range of cancers and infectious diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/19/24 | $54,000,000 | Series A |
Cockrell Interests Sandia Holdings Tanis Venture Management Ziff Capital Partners  | undisclosed |
